Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer Clinical Trial

Official title:
A Randomized, Controlled, Open-label Phase II/III Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel / HB1801 in Patients With sqNSCLC

Status Not yet recruiting

Clinical Trial Summary

This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Squamous Cell Non-small Cell Lung Cancer

Clinical Trial Details

NCT number	NCT06319313
Study type	Interventional
Source	Shanghai JMT-Bio Inc.
Contact	Clinical Trials Information Group officer
Phone	86-0311-69085587
Email	ctr-contact@cspc.cn
Status	Not yet recruiting
Phase	Phase 2/Phase 3
Start date	May 1, 2024
Completion date	December 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02283320` - A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT01642004` - Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)	Phase 3
Completed	`NCT01721759` - Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens	Phase 2
Recruiting	`NCT05429463` - Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）	Phase 3